Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer
Prostate cancer is one of the most prevalent types of cancer among men. It is stimulated by the androgens, or male sexual hormones, which circulate in the blood and diffuse into the tissue where they stimulate the prostate tumor to grow. One of the most important treatments for advanced prostate can...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIMS Press
2017-05-01
|
| Series: | Mathematical Biosciences and Engineering |
| Subjects: | |
| Online Access: | https://www.aimspress.com/article/doi/10.3934/mbe.2017043 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590046187749376 |
|---|---|
| author | Alacia M. Voth John G. Alford Edward W. Swim |
| author_facet | Alacia M. Voth John G. Alford Edward W. Swim |
| author_sort | Alacia M. Voth |
| collection | DOAJ |
| description | Prostate cancer is one of the most prevalent types of cancer among men. It is stimulated by the androgens, or male sexual hormones, which circulate in the blood and diffuse into the tissue where they stimulate the prostate tumor to grow. One of the most important treatments for advanced prostate cancer has become androgen deprivation therapy (ADT). In this paper we present three different models of ADT for prostate cancer: continuous androgen suppression (CAS), intermittent androgen suppression (IAS), and periodic androgen suppression. Currently, many patients in the U.S. receive CAS therapy of ADT, but many undergo a relapse after several years and experience adverse side effects while receiving treatment. Some clinical studies have introduced various IAS regimens in order to delay the time to relapse, and/or to reduce the economic costs and adverse side effects. We will compute and analyze parameter sensitivity analysis for CAS and IAS which may give insight to plan effective data collection in a future clinical trial. Moreover, a periodic model for IAS is used to develop an analytical formulation for relapse times which then provides information about the sensitivity of relapse to the parameters in our models. |
| format | Article |
| id | doaj-art-58317a0ba0934223b91f1f3b7f9c8271 |
| institution | Kabale University |
| issn | 1551-0018 |
| language | English |
| publishDate | 2017-05-01 |
| publisher | AIMS Press |
| record_format | Article |
| series | Mathematical Biosciences and Engineering |
| spelling | doaj-art-58317a0ba0934223b91f1f3b7f9c82712025-01-24T02:39:47ZengAIMS PressMathematical Biosciences and Engineering1551-00182017-05-0114377780410.3934/mbe.2017043Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancerAlacia M. Voth0John G. Alford1Edward W. Swim2United Services Automobile Association, 9800 Fredericksburg Rd, San Antonio, TX 78288, USASam Houston State University, Department of Mathematics and Statistics, Huntsville, TX 77341, USASam Houston State University, Department of Mathematics and Statistics, Huntsville, TX 77341, USAProstate cancer is one of the most prevalent types of cancer among men. It is stimulated by the androgens, or male sexual hormones, which circulate in the blood and diffuse into the tissue where they stimulate the prostate tumor to grow. One of the most important treatments for advanced prostate cancer has become androgen deprivation therapy (ADT). In this paper we present three different models of ADT for prostate cancer: continuous androgen suppression (CAS), intermittent androgen suppression (IAS), and periodic androgen suppression. Currently, many patients in the U.S. receive CAS therapy of ADT, but many undergo a relapse after several years and experience adverse side effects while receiving treatment. Some clinical studies have introduced various IAS regimens in order to delay the time to relapse, and/or to reduce the economic costs and adverse side effects. We will compute and analyze parameter sensitivity analysis for CAS and IAS which may give insight to plan effective data collection in a future clinical trial. Moreover, a periodic model for IAS is used to develop an analytical formulation for relapse times which then provides information about the sensitivity of relapse to the parameters in our models.https://www.aimspress.com/article/doi/10.3934/mbe.2017043prostate cancerandrogen suppressiondifferential equationssensitivity functionsrelapse |
| spellingShingle | Alacia M. Voth John G. Alford Edward W. Swim Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer Mathematical Biosciences and Engineering prostate cancer androgen suppression differential equations sensitivity functions relapse |
| title | Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer |
| title_full | Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer |
| title_fullStr | Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer |
| title_full_unstemmed | Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer |
| title_short | Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer |
| title_sort | mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer |
| topic | prostate cancer androgen suppression differential equations sensitivity functions relapse |
| url | https://www.aimspress.com/article/doi/10.3934/mbe.2017043 |
| work_keys_str_mv | AT alaciamvoth mathematicalmodelingofcontinuousandintermittentandrogensuppressionforthetreatmentofadvancedprostatecancer AT johngalford mathematicalmodelingofcontinuousandintermittentandrogensuppressionforthetreatmentofadvancedprostatecancer AT edwardwswim mathematicalmodelingofcontinuousandintermittentandrogensuppressionforthetreatmentofadvancedprostatecancer |